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INTRODUCTION
Therapy-related myeloid neoplasms (t-MN), also referred to as therapy-related myelodysplastic syndromes (t-MDS) and therapy-related acute myeloid leukemia (t-AML), are well characterized and accepted in current classification systems (1) . t-MN secondary to alkylating agents or ionizing-radiation is frequently associated with unbalanced loss of genetic material, most often involving chromosomes 5 and/or 7. t-MN post DNA topoisomerase II inhibitor therapy is commonly associated with balanced chromosomal translocations, and more commonly presents as overt t-AML (1) . In contrast to the accepted pathogenic role of chemoradiation therapy in t-MN (1), the possible role of prior therapy in patients who subsequently develop precursor B-acute lymphoblastic leukemia (B-ALL) is much less clear.
Precursor B-ALL is characterized by a proliferation of lymphoblasts arrested at an early stage of B-cell maturation. Precursor B-ALL occurring in patients with prior malignancies, for convenience henceforth referred as secondary precursor B-ALL here, is uncommon and the relationship of these neoplasms to prior cytotoxic therapy is largely debatable. The Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto 4 (GIMEMA) Archive of Adult Acute Leukemia(2) from 62 Hematologic Divisions reported secondary ALL in 21 of 901 (2.3%) adults. Notably, 10 of these patients did not receive prior chemoradiotherapy but had multiple cancers or a family history of cancer. The study raised the question: is secondary ALL a direct result from prior cytotoxic therapy, is it simply occurred as a random event, or is it related to a familial predisposition to cancer? Later studies, mostly case studies or small case series with a summary of cases reported in the literature, reported various findings that led to different conclusions (3) (4) (5) . Notably, the subjects reported in those studies were both adults and children with a mixture of precursor B-and T-acute lymphoblastic leukemia/lymphoma, and the clinicopathological and molecular genetic features of these neoplasms are difficult to delineate. Furthermore, "therapy-related ALL" has been interchangeably with "secondary ALL" in many of the references, adding to the confusion. Nevertheless, there is a suggestion, particularly in the study by Ishizawa S et al (6) , that secondary precursor B-ALL with 11q23 abnormalities were related to toposomerase II inhibitor therapy (3, 4, 6) . Secondary precursor B-ALL associated with other cytogenetic abnormalities, however, remains to be clarified.
In this study we reviewed all precursor B-ALL patients diagnosed or referred to our hospital in the past 6 years to identify patients with a history of other malignancies. With this large cohort, we examined in detail the treatment history, clinical features, and cytogenetic findings in patients with secondary precursor B-ALL to determine if these cases are therapy-related, analogous to t-MN.
DESIGN AND METHODS
Study Group
The diagnosis of precursor B-ALL was rendered according to criteria established by the World Health Organization (WHO). reviewed. Only adult patients (≥18 yo) were included. For cases with initial diagnosis made at the referring hospital, the pathologic materials used for establishing the initial diagnosis were reviewed in our department. To focus this study on precursor B-ALL, cases of acute leukemia of ambiguous lineage, either biphenotypic or bilineal were excluded. Cases of B-lymphoblastic crisis of chronic myelogeneous leukemia (CML) as well as leukemic presentation of Burkitt lymphoma were also excluded. The study was approved by the institutional review board (IRB) of MDACC.
A detailed chart review was conducted in all patients, with specific attention to prior history of malignancies and related therapy. Treatment was categorized as chemotherapy, chemotherapy plus radiation; and radiation alone. The chemotherapy agents were further categorized as alkylating; toposomerase II inhibitors; and others (antimetabolites and antitubulin agents) (1) . Patients who received brachytherapy or radioisotopes (radioactive iodine) only were not considered as having prior cytotoxic therapy (1) . For the purpose of simplification, patients with prior malignancy and who received chemotherapy and/or radiation were designated as Group 1 (secondary precursor B-ALL with prior cytotoxic therapy); Patients with prior malignancy but no cytotoxic therapy were designated as Group 2 (secondary precursor B-ALL without prior 6 cytotoxic therapy); and patients without prior malignancy were designated as Group 3 (de novo precursor B-ALL).
Frontline chemotherapy was administered using the hyper-CVAD regimen (hyperfractionated cyclophosphamide, vincristine, doxorubicin, dexamethasone alternating with high dose methotrexate and cytarabine) in adults with Ph negative precursor B-ALL as previously described (8) . Ph-positive precursor B-ALL patients were treated with the hyper-CVAD regimen concurrently with either imatinib mesylate or dasatinib as previously reported (9) . Treatment was not different between secondary or de novo precursor B-ALL.
Laboratory Data and Bone Marrow Assessment
Peripheral blood smears, bone marrow (BM) aspirate smears and trephine biopsy specimens were reviewed. Blast percentage, bone marrow cellularity, and background dysplasia were assessed. Myeloperoxidase (MPO) cytochemistry stain was performed on all cases.. The white blood cell (WBC) and platelet counts and the hemoglobin (Hb), lactate dehydrogenase (LDH), creatinine, and albumin levels were recorded in most patients.
Flow Cytometric Immunophenotyping
Flow cytometry immunophenotyping was performed using a panel of antibodies designed for acute leukemia and further analyzed by an extended panel designed for precursor B-ALL according to the methods described previously (9) . All precursor B-ALL cases expressed CD19 in conjunction with at least one other B-lineage marker (CD22, CD79a, and/or cIgM), and were negative for cCD3 and myeloproxidase. These results were essential to confirm a diagnosis of precursor B-ALL.
Conventional Karyotyping and Fluorescence in Situ Hybridization (FISH)
Conventional chromosomal analysis was performed on G-banded metaphase cells prepared from unstimulated BM aspirate cultures using standard techniques. Twenty metaphases were analyzed and the results were reported using the International System for Human Cytogenetic Nomenclature. 
Statistical Analysis
The Mann-Whitney test was used for numerical comparison between two groups. Fisher exact and chi-square tests were applied for categorical variables. 
RESULTS
Patients
A total of 457 patients with precursor B-ALL were included in this study. 
Bone marrow findings
In de novo precursor B-ALL patients, 388 (94%) patients presented as leukemia; whereas 25 (6%) patients presented with B-lymphoblastic lymphoma with minimal (<25%) or no BM involvement. In contrast, all patients with secondary precursor B-ALL presented as leukemia. All precursor B-ALL cases, either de novo or secondary, demonstrated a hypercellular BM with a high percentage of lymphoblasts. Although dysplasia in hematopoietic cells was observed in some cases, in most patients the numbers of hematopoietic cells were too few for accurate assessment.
Cytogenetic and molecular features
The cytogenetic characteristics of precursor B-ALL are shown in Table 1 . BCR/ABL1
FISH and/or RT-PCR were performed in essentially all cases. We observed no significant differences in karyotypic findings between de novo and secondary precursor B-ALL without prior cytotoxic chemotherapy, except for a slightly higher frequency of Ph+ in the latter group. We then compared the cytogenetic findings in patients with cytotoxic therapy (Group 1) versus patients without prior cytotoxic therapy (Groups 2 &3). In Group 1, 5 patients (17%) had a normal karyotype and 7 patients (24%) had BCR/ABL1 fusion; the incidence of these findings was similar to patients without prior cytotoxic therapy. Notably, among these 12 patients, 5 received radiation only and 2
received only a purine analog. The frequency of t(4;11)(q21;q23) involving MLL was significantly higher in Group 1 patients (n=7, 24%; p<0.001), and all 7 patients received toposomerase II inhibitor and alkylating agent containing regimens (Table 2) .
Hypodiploidy, particularly with loss of chromosomes 5, 7, or 17, was significantly more frequently in Group 1 patients (n=6, 21%, p=0.009); all 6 patients in this group received alkylating agent containing chemotherapy (Table 2 ). None patients with secondary precursor B-ALL had t(1;19)(q23;p13.3) and other cytogenetic alterations were also uncommon.
Class I mutations, including FLT3, RAS (K-RAS/N-RAS) and KIT, were tested in a subset of patients and the frequencies were similarly low among the three groups: albumin, LDH and creatinine were co-analyzed for both OS and EFS (Table 3) .
DISCUSSION
In this study we analyzed a large cohort of precursor B-ALL patients treated at one institution with detailed clinical data and follow-up information available. We show that secondary precursor B-ALL represents approximately 9-10% of all precursor B-ALL in adults. Several cytogenetic alterations, including t(4;11)(q21;q23) and hypodiploidy with loss of chromosomes 5, 7, 17, were likely related to prior cytotoxic therapy. (14) . MLL/AF4 fusions have not only been found in CD19+ cells, but also in CD34+CD19-cells (15) . It appears that in the therapy-related setting, toposomerase II inhibitors can cause MLL gene rearrangements with various partner genes; whereas most of these rearrangements lead to t-MN, MLL/AF4 occurs in primitive but lymphoid-restricted progenitor/stem cells, leading clinical precursor B-ALL.
Two of 28 MLL/AF4 cases were biphenotypic, but were not therapy-related. A study of acute leukemia with ambiguous lineages in relation to prior therapy may be interesting, but was not addressed in this study. We showed that patients with t(4;11)(q21;q23) in Group 1 were older than their de novo counterpart, and therefore less likely qualified for SCT. Otherwise, the clinical laboratory findings, morphology and immunophenotype of the blasts, and responses to hyper-CVAD were very similar and appeared to be denoted by the presence of MLL/AF4 fusion.
Hypodiploidy in either pediatric or adult precursor B-ALL represents approximately 5%
or less of all precursor B-ALL (16, 17) and confers to a poor prognosis. Loss of chromosome 7 is known to be an adverse prognostic indicator in pediatric precursor B-ALL, and is frequently observed in cases with hypodiploidy (18) . Analysis of deleted regions indicated that loss of 7p rather than 7q was critical prognostically (18); and precursor B-ALL with -7 and -7p was distinct from myeloid disorders with -7 and -7q.
Loss of chromosome of 17 in precursor B-ALL has been rarely reported (19) . A recent study using single nucleotide polymorphism oligonucleotide microarray reported microdeletion of 17p (TP53) in 11% of all adult precursor B-ALL (20) . We found that hypodiploidy, particularly with complete loss of chromosome 5, 7 and 17(17p), were significantly higher in Group 1 patients and all these patients received alkylating agents.
This finding is in parallel to the common cytogenetic alterations reported in t-MN post alkylating chemotherapy. Intriguingly, t-MN with loss of 5 and 7 often have 44-46 chromosomes (data not shown) whereas precursor B-ALL with a hypodiploidy has a lower number of chromosomes, often <44.
We showed that the frequencies of a normal karyotype and the Ph-chromosome were similar in de novo and secondary precursor B-ALL. In fact, Ph+ was slightly more frequent in Group 2 patients, which might be explained by a natural rise of Ph+ precursor B-ALL cases in older patients (21) , and variation due to a small number of cases in group 2. Notably, we showed that of the 12 patients with a normal karyotype (n=5) or Ph+ (n=7) in group 1, two received purine analog only and 5 local radiation. In the past two decades, the field of radiation therapy (XRT) has moved towards using more conformal treatment techniques that reduce the exposure of hematopoietic bone marrow. We recently reviewed (22) 47 patients who developed MDS/AML following XRT alone in the past decade may not be a direct consequence of radiation toxicity. On the other hand, single agent purine analog therapy rarely causes t-MN (23, 24) . The findings from our series indicate that secondary precursor B-ALL with a normal karyotype or Ph+ may not be related to prior cytotoxic exposure, and more likely is a coincidence or reflects individual genetic susceptibility to cancer.
Patients with secondary precursor B-ALL had an inferior survival; and the differences were likely attributed to the poor-risk cytogenetic abnormalities in these patients as a result of cytotoxic exposures and older age. We observed no difference in outcome of Group 1 and Group 2 patients, which could be explained by a high proportion of Ph+ in the Group 2. Importantly, some of the "cytotoxic agents" such as local radiation alone and purine analogs might not necessarily be leukemogenic as discussed above. Unlike therapy-related AML (25, 26) , a history of prior therapy was not an independent unfavorable factor with respect to survival. The fundamental differences between precursor B-ALL and AML in clinical, molecular/genetic and biological characteristics as well as the number of cases studied may be contributing factors. Nevertheless, our data indicate that secondary precursor B-ALL can be stratified by the current precursor B-ALL risk stratification system similar to de novo precursor B-ALL, where cytogenetics appears to be the most important factor in predicting survival. 16 In summary, we demonstrate that a subset of secondary precursor B-ALL cases is therapy-related, and linked to previous alkylating agent or toposomerase II inhibitor treatment. These cases exhibit characteristic cytogenetic alterations related to different cytotoxic exposures, similar to those described in patients with therapy-related myeloid neoplasms. It is biologically interesting and unexplained why similar cytogenetic alterations confer to the development of precursor B-ALL rather than myeloid neoplasms in the post-therapy setting. Class I mutations including FLT3, RAS and KIT were similarly infrequent in de novo and therapy-related cases of precursor B-ALL in our study. The prognosis of patients with secondary precursor B-ALL, either therapy-related or not related, is poor, likely attributable to their associated high-risk cytogenetic abnormalities they harbor.
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